125 related articles for article (PubMed ID: 1835941)
21. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
22. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor.
Kinoshita T; Thyphronitis G; Tsokos GC; Finkelman FD; Hong K; Sakai H; Inoue K
Int Immunol; 1990; 2(7):651-9. PubMed ID: 1703784
[TBL] [Abstract][Full Text] [Related]
23. Expression of a cell adhesion protein (VLA beta) in normal and diseased skin.
Ralfkiaer E; Thomsen K; Vejlsgaard GL
Br J Dermatol; 1991 Jun; 124(6):527-32. PubMed ID: 1712220
[TBL] [Abstract][Full Text] [Related]
24. Tissue distribution of the C3d/EBV-receptor: CD21 monoclonal antibodies reactive with a variety of epithelial cells, medullary thymocytes, and peripheral T-cells.
Timens W; Boes A; Vos H; Poppema S
Histochemistry; 1991; 95(6):605-11. PubMed ID: 1830299
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody OKB19, reactive with a B-lymphoid differentiation antigen (CD19), binding to basal layer keratinocytes of normal human skin.
Watanabe S; Ichikawa E; Wagatsuma K; Kawa Y; Takahashi H
J Dermatol; 1991 Sep; 18(9):517-22. PubMed ID: 1724003
[TBL] [Abstract][Full Text] [Related]
26. Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells.
Larcher C; Schulz TF; Hofbauer J; Hengster P; Romani N; Wachter H; Dierich MP
J Acquir Immune Defic Syndr (1988); 1990; 3(2):103-8. PubMed ID: 2136911
[TBL] [Abstract][Full Text] [Related]
27. Reaction of human keratinocytes with the monoclonal antibody anti-Leu-11: an immunohistologic study.
Niedecken H; Wehrmann W; Bauer R; Kreysel HW
J Am Acad Dermatol; 1988 Mar; 18(3):504-10. PubMed ID: 2450899
[TBL] [Abstract][Full Text] [Related]
28. The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line.
Pillemer SR; Tsokos GC; Barbieri SA; Balow JE; Golding B
Cell Immunol; 1990 Feb; 125(2):386-95. PubMed ID: 1688740
[TBL] [Abstract][Full Text] [Related]
29. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
[TBL] [Abstract][Full Text] [Related]
30. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases.
Novelli M; Savoia P; Fierro MT; Verrone A; Quaglino P; Bernengo MG
Br J Dermatol; 1996 Jun; 134(6):1052-6. PubMed ID: 8763423
[TBL] [Abstract][Full Text] [Related]
31. Cell-bound IgE and increased expression of Fc epsilon-receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides.
Preesman AH; Van de Winkel JG; Magnusson CG; Toonstra J; van der Putte SC; van Vloten WA
Clin Exp Immunol; 1991 Nov; 86(2):246-51. PubMed ID: 1834378
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.
June RA; Landay AL; Stefanik K; Lint TF; Spear GT
Immunology; 1992 Jan; 75(1):59-65. PubMed ID: 1371493
[TBL] [Abstract][Full Text] [Related]
33. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.
Kalli KR; Hsu PH; Bartow TJ; Ahearn JM; Matsumoto AK; Klickstein LB; Fearon DT
J Exp Med; 1991 Dec; 174(6):1451-60. PubMed ID: 1836011
[TBL] [Abstract][Full Text] [Related]
34. Expression of CR2 (C3d receptor) on the cell membranes of adult T cell leukemia.
Kai C; Okada N; Okada H
Jpn J Cancer Res; 1988 Jul; 79(7):805-8. PubMed ID: 2971638
[TBL] [Abstract][Full Text] [Related]
35. Detection of transferrin and C3d receptors in the skin of patients with various dermatoses.
Juhlin L
Acta Derm Venereol; 1989; 69(6):492-6. PubMed ID: 2575321
[TBL] [Abstract][Full Text] [Related]
36. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.
Tuveson DA; Ahearn JM; Matsumoto AK; Fearon DT
J Exp Med; 1991 May; 173(5):1083-9. PubMed ID: 1708808
[TBL] [Abstract][Full Text] [Related]
37. Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma.
Kado JA; Shango M; Mehregan C; Mehregan DR
Am J Dermatopathol; 2012 Oct; 34(7):691-8. PubMed ID: 22407070
[TBL] [Abstract][Full Text] [Related]
38. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
39. [Disordered keratinocyte differentiation in epidermal tumors and mycosis fungoides].
Vavilov AM; Beletskaia LV; Drobyshevakaia EI; Persina IS
Vestn Dermatol Venerol; 1989; (1):26-9. PubMed ID: 2470216
[TBL] [Abstract][Full Text] [Related]
40. A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.
Freysdottir J; Sigfusson A
J Immunol Methods; 1991 Aug; 142(1):45-52. PubMed ID: 1833467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
